Golino et al., 2000 - Google Patents
Recombinant human, active site-blocked factor VIIa reduces infarct size and no-reflow phenomenon in rabbitsGolino et al., 2000
View HTML- Document ID
- 2730973589500515563
- Author
- Golino P
- Ragni M
- Cirillo P
- Scognamiglio A
- Ravera A
- Buono C
- Guarino A
- Piro O
- Lambiase C
- Botticella F
- Ezban M
- Condorelli M
- Chiariello M
- Publication year
- Publication venue
- American Journal of Physiology-Heart and Circulatory Physiology
External Links
Snippet
Oxygen free radicals induce de novo synthesis of tissue factor (TF), the initiator of the extrinsic pathway of coagulation, within the coronary vasculature during postischemic reperfusion. In the present study we wanted to assess whether TF expression might cause …
- 206010061216 Infarction 0 title abstract description 35
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/49—Urokinase; Tissue plasminogen activator
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Golino et al. | Recombinant human, active site-blocked factor VIIa reduces infarct size and no-reflow phenomenon in rabbits | |
| Kharbanda et al. | Functions of the healthy endothelium | |
| Golino et al. | Effects of tissue factor induced by oxygen free radicals on coronary flow during reperfusion | |
| Ito et al. | Endotheliopathy in septic conditions: mechanistic insight into intravascular coagulation | |
| De Caterina et al. | General mechanisms of coagulation and targets of anticoagulants (Section I) | |
| Rijken et al. | Basic principles in thrombolysis: regulatory role of plasminogen | |
| Yau et al. | Endothelial cell control of thrombosis | |
| Okorie et al. | Determination of surface tissue factor thresholds that trigger coagulation at venous and arterial shear rates: amplification of 100 fM circulating tissue factor requires flow | |
| Larsen et al. | Thrombin: a pivotal player in hemostasis and beyond | |
| Esmon | The endothelial cell protein C receptor | |
| Ait-Oufella et al. | The endothelium: physiological functions and role in microcirculatory failure during severe sepsis | |
| Price et al. | Tissue factor and tissue factor pathway inhibitor | |
| Ivanciu et al. | Spatiotemporal regulation of coagulation and platelet activation during the hemostatic response in vivo | |
| US6238878B1 (en) | FVlla/TF activity inhibiting compounds | |
| Campbell et al. | Activation of the kallikrein-kinin system by cardiopulmonary bypass in humans | |
| US6849617B2 (en) | Tissue factor antagonists and methods of use thereof | |
| Abendschein et al. | Maintenance of coronary patency after fibrinolysis with tissue factor pathway inhibitor | |
| Levin et al. | Impact of microparticles derived from erythrocytes on fibrinolysis | |
| Crutchley et al. | The stable prostacyclin analog, iloprost, and prostaglandin E1 inhibit monocyte procoagulant activity in vitro | |
| Suzuki et al. | Enhancement of fibrinolysis by EF6265 [(S)-7-amino-2-[[[(R)-2-methyl-1-(3-phenylpropanoylamino) propyl] hydroxyphosphinoyl] methyl] heptanoic acid], a specific inhibitor of plasma carboxypeptidase B | |
| Noguchi et al. | Fibrinolytic potential of DS-1040, a novel orally available inhibitor of activated thrombin-activatable fibrinolysis inhibitor (TAFIa) | |
| von dem Borne et al. | Factor XI enhances fibrin generation and inhibits fibrinolysis in a coagulation model initiated by surface-coated tissue factor | |
| Hathcock | Vascular biology—the role of tissue factor | |
| Kubo-Inoue et al. | Long-term inhibition of nitric oxide synthesis increases arterial thrombogenecity in rat carotid artery | |
| McMichael | Overview of hemostasis |